Sign In
Buy BCLI
$0.770
-0.0217 (-2.74%)
At Close: Jun 03, 2026
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment
08:00am, Thursday, 28'th Sep 2023
BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a thumbs-down to the company's investigat
FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics
07:36pm, Wednesday, 27'th Sep 2023
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS.
US FDA panel votes against BrainStorm's ALS therapy
06:10pm, Wednesday, 27'th Sep 2023
The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapy
11:28am, Monday, 25'th Sep 2023
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers expressed doubts over the safety and efficacy of th
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
08:38am, Monday, 25'th Sep 2023
The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotrophic lateral sclerosis (ALS) therapy, sending the
Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
06:03pm, Friday, 15'th Sep 2023
BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly bet
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Brainstorm Cell (NASDAQ:BCLI), Cosmos Health (NASDAQ:COSM)
07:46am, Thursday, 27'th Jul 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update
06:00am, Tuesday, 09'th May 2023
NEW YORK , May 9, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a c
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
08:18am, Tuesday, 21'st Mar 2023
NEW YORK , March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
04:10pm, Monday, 07'th Nov 2022
NEW YORK , Nov. 7, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it w
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
03:57am, Sunday, 21'st Aug 2022
Brainstorm Cell Therapeutics is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. NurOwn's mechanism of action relies on bringing down neuroinflammation and alteri
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
06:00am, Monday, 01'st Aug 2022
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call Transcript
10:20am, Monday, 16'th May 2022
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Tom Galassi - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
06:00am, Monday, 02'nd May 2022
NEW YORK , May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company wil
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
02:29pm, Monday, 28'th Mar 2022
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
